These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 38553819

  • 1. Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study.
    Custodio LFP, Martins SBS, Viana LA, Cristelli MP, Requião-Moura L, Chow CYZ, Camargo SFDN, Nakamura MR, Foresto RD, Tedesco-Silva H, Medina-Pestana J.
    Pediatr Transplant; 2024 May; 28(3):e14713. PubMed ID: 38553819
    [Abstract] [Full Text] [Related]

  • 2. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 3. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W, Yin H, Li XB, Hu XP, Yang XY, Liu H, Ren L, Wang Y, Zhang XD.
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [Abstract] [Full Text] [Related]

  • 4. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 5. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Oct; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 6. Belatacept for kidney transplant recipients.
    Masson P, Henderson L, Chapman JR, Craig JC, Webster AC.
    Cochrane Database Syst Rev; 2014 Nov 24; 2014(11):CD010699. PubMed ID: 25416857
    [Abstract] [Full Text] [Related]

  • 7. Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study.
    Martinez-Mier G, Moreno-Ley PI, Budar-Fernández LF, Méndez-López MT, Allende-Castellanos CA, Jiménez-López LA, Barrera-Amoros DA, Reyes-Ruiz JM.
    Arch Med Res; 2024 Sep 24; 55(6):103047. PubMed ID: 39079480
    [Abstract] [Full Text] [Related]

  • 8. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S.
    Saudi J Kidney Dis Transpl; 2014 Jan 24; 25(1):9-15. PubMed ID: 24434376
    [Abstract] [Full Text] [Related]

  • 9. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience.
    Lee H, Lee S, Jeon JS, Kwon SH, Noh H, Han DC, Yun S, Song D.
    Transplant Proc; 2018 Jun 24; 50(5):1285-1288. PubMed ID: 29880348
    [Abstract] [Full Text] [Related]

  • 10. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.
    Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759
    [Abstract] [Full Text] [Related]

  • 11. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM, Keating GM.
    Drugs; 2003 Dec 17; 63(24):2803-35. PubMed ID: 14664658
    [Abstract] [Full Text] [Related]

  • 12. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA, Felipe CR, Santos RHN, Medina Pestana JO, Tedesco-Silva Junior H.
    Ther Drug Monit; 2020 Dec 17; 42(6):811-820. PubMed ID: 32657909
    [Abstract] [Full Text] [Related]

  • 13. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
    Zang S, Zhang X, Niu J, Das BB.
    Clin Transplant; 2023 Jan 17; 37(1):e14836. PubMed ID: 36259556
    [Abstract] [Full Text] [Related]

  • 14. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, Guillemain R, Lelong B, Pol A, Treilhaud M, Vermes E, Dorent R, Lemay D, Blanc AS, Boissonnat P.
    J Heart Lung Transplant; 2007 Jul 17; 26(7):693-9. PubMed ID: 17613399
    [Abstract] [Full Text] [Related]

  • 15. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 17; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 16. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 17. A comparative analysis of kidney allograft outcomes in steroid use versus steroid discontinuation after basiliximab and ATG induction: A UNOS database study.
    Nissaisorakarn P, Patel H, Cardarelli F, Amtul A.
    Clin Nephrol; 2024 Jul 27; 102():39-50. PubMed ID: 38699983
    [Abstract] [Full Text] [Related]

  • 18. Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab.
    Ansari D, Lund LH, Stehlik J, Andersson B, Höglund P, Edwards L, Nilsson J.
    J Heart Lung Transplant; 2015 Oct 27; 34(10):1283-91. PubMed ID: 26087667
    [Abstract] [Full Text] [Related]

  • 19. Impact of induction strategy change on first-year rejection in pediatric heart transplantation at a single center-From postoperative basiliximab to either postoperative anti-thymocyte globulin or preoperative basiliximab.
    Sisson TM, Padilla LA, Hubbard M, Smith S, Pearce FB, Collins JL, Carlo WF.
    Clin Transplant; 2021 Jun 27; 35(6):e14314. PubMed ID: 33838071
    [Abstract] [Full Text] [Related]

  • 20. Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation.
    Clinckart F, Bulpa P, Jamart J, Eucher P, Delaunois L, Evrard P.
    Transplant Proc; 2009 Mar 27; 41(2):607-9. PubMed ID: 19328937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.